NeuroMetrix, Inc. (NASDAQ:NURO) Sees Significant Decrease in Short Interest

NeuroMetrix, Inc. (NASDAQ:NURO) saw a large decrease in short interest during the month of March. As of March 15th, there was short interest totalling 1,600 shares, a decrease of 36.0% from the February 28th total of 2,500 shares. Currently, 0.1% of the company’s stock are short sold. Based on an average daily volume of 18,000 shares, the short-interest ratio is presently 0.1 days.

Hedge Funds Weigh In On NeuroMetrix

An institutional investor recently bought a new position in NeuroMetrix stock. GTS Securities LLC acquired a new position in shares of NeuroMetrix, Inc. (NASDAQ:NURO) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 22,759 shares of the medical device company’s stock, valued at approximately $90,000. GTS Securities LLC owned about 1.12% of NeuroMetrix as of its most recent SEC filing. Hedge funds and other institutional investors own 19.40% of the company’s stock.

NeuroMetrix Stock Performance

NASDAQ:NURO traded down $0.08 during mid-day trading on Friday, hitting $4.43. 2,608 shares of the company’s stock traded hands, compared to its average volume of 17,481. NeuroMetrix has a 1 year low of $2.66 and a 1 year high of $4.73. The company has a market cap of $9.09 million, a PE ratio of -0.97 and a beta of 2.15. The firm’s 50 day simple moving average is $4.35 and its 200 day simple moving average is $4.15.

Analyst Upgrades and Downgrades

Separately, StockNews.com initiated coverage on shares of NeuroMetrix in a research report on Friday. They set a “sell” rating for the company.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.